MIWG was formed in 2006 to seek clarity in the FDA regulatory scheme regarding the dissemination of truthful non-misleading information about prescription drugs, biological products and medical devices, and to improve the federal regulatory framework and enforcement climate affecting manufacturer dissemination of information regarding those products (including products in development and new uses of marketed products).

Resources

FDA Submissions and Amicus Briefs Filed on Behalf of MIWG Members.

Re: Draft Guidance for Industry: Addressing Misinformation About Medical Devices and Prescription Drugs: Questions and Answers (Docket No. FDA-2014-D-0447)
September 9, 2024
Download PDF »
Revised Draft Guidance for Industry: “Communications From Firms to Health Care Providers Regarding Scientific Information on Unapproved Uses of Approved/Cleared Medical Products” (Docket No. FDA-2008-D-0053)
January 5, 2024
Download PDF »
UNITED STATES, EX REL. TRACY SCHUTTE, ET AL., PETITIONERS v. SUPERVALU INC., ET AL.
March 1, 2023
Download PDF »
United States v. Patrick Fabian: Brief of Members of the Medical Information Work Group as Amici Curiae in Support of Reversal
July 28, 2021
Download PDF »
United States v. William Facteau: Brief of Members of the Medical Information Working Group as Amici Curiae in Support of Reversal
July 28, 2021
Download PDF »
Regulations Regarding “Intended Uses”
June 30, 2021
Download PDF »
MIWG Comments on Intended Use Proposed Rule
October 23, 2020
Download PDF »
Medical Information Working Group (MIWG); Recent Case Law Developments
November 21, 2019
Download PDF »
COMMENT FROM THE MEDICAL INFORMATION WORKING GROUP RE: Prescription Drug-Use-Related Software; Establishment of a Public Docket; Request for Comments (Docket No. FDA-2018-N-3017) (January 22, 2019)
January 23, 2019
Download PDF »
Regulation To Require Drug Pricing Transparency; Request for Comments, Docket No. CMS-4187-P, 83 Fed. Reg. 52,789 (Oct. 18, 2018)
December 17, 2018
Download PDF »
Amendments to Regulations Regarding “Intended Uses”; Proposed Partial Delay of Effective Date (Docket Nos. FDA-2015-N-2002, FDA-2017-D-4792, and -6580)
February 5, 2018
Download PDF »
Review of Existing CDER/CDRH Regulatory and Information Collection Requirements; Request for Comments and Information (Docket Nos. FDA-2017-N-501 and FDA-2017-N-5105).
December 7, 2017
Download PDF »
Comment from the Medical Information Working Group re: FDA's Draft Guidance on Microneedling Devices
November 14, 2017
Download PDF »
Comment from the Medical Information Working Group re: FDA's "Intended Use" Final Rule
July 18, 2017
Download PDF »
Comment from the Medical Information Working Group re: Manufacturer Communications Regarding Unapproved Uses of Approved or Cleared Medical Products
April 19, 2017
Download PDF »
Request for Extension from MIWG, PhRMA and BIO
April 5, 2017
Download PDF »
Petition to Stay and for Reconsideration
February 8, 2017
Download PDF »
Testimony prepared for Food and Drug Administration (FDA) hearing on “Manufacturer Communications Regarding Unapproved Uses of Approved or Cleared Medical Products.
November 9, 2016
Download PDF »
Amicus Brief in United States v. Facteau and Fabian
September 19, 2016
Download PDF »
Comment to FDA Proposed Rule Regarding Amendments to Intended Use Regulations
November 24, 2015
Download PDF »
Amicus Brief in Pacira Pharmaceuticals, Inc. v. FDA
October 15, 2015
Download PDF »
Amicus Brief in Amarin Pharma, Inc. v. FDA
June 11, 2015
Download PDF »
Use of Health Care Economic Information Under Section 114 of the Food and Drug Administration Modernization Act
October 31, 2014
Download PDF »
White Paper: Systemic, Societal, and Legal Developments Require Changes To FDA’s Regulation of Manufacturer Speech
October 31, 2014
Download PDF »
Comments to FDA Draft Guidance for Industry: Internet/Social Media Platforms with Character Space Limitations—Presenting Risk and Benefit Information for Prescription Drugs and Medical Devices
September 16, 2014
Download PDF »
Comments to FDA Draft Guidance for Industry: Internet/Social Media Platforms: Correcting Independent Third-Party Misinformation About Prescription Drugs and Medical Devices
September 16, 2014
Download PDF »
Comments to FDA Draft Guidance for Industry: Distributing Scientific and Medical Publications on Risk Information for Approved Prescription Drugs and Biological Products - Recommended Practices
August 25, 2014
Download PDF »
Comments Re FDA Draft Strategic Priorities for 2014–2018
July 31, 2014
Download PDF »
Comments to FDA Draft Guidance for Industry: Distributing Scientific and Medical Publications on Unapproved New Uses - Recommended Practices
May 2, 2014
Download PDF »
Comment to FDA Draft Guidance for Industry: Fulfilling Regulatory Requirements for Postmarketing Submissions of Interactive Promotional Media for Prescription Human and Animal Drugs and Biologics
April 14, 2014
Download PDF »
Comments re FDA Safety and Innovation Act Section 907 Report
November 20, 2013
Download PDF »
Second Citizen Petition Submitted to FDA on Behalf of Members of the MIWG
September 3, 2013
Download PDF »
Comments re CDER Medical Policy Council
July 16, 2013
Download PDF »
Letter to FDA re Fox II and Caronia Decisions
March 1, 2013
Download PDF »
Comments to FDA re Scientific Exchange and Draft Guidance to Industry on Unsolicited Requests
March 27, 2012
Download PDF »
Amicus Brief in United States v. Caronia
August 22, 2011
Download PDF »
First Citizen Petition Submitted to FDA on Behalf of Members of the MIWG
July 5, 2011
Download PDF »
Comments re FDA Transparency Task Force
April 15, 2010
Download PDF »
Comments to FDA Draft Guidance for Industry: Good Reprint Practices for the Distribution for Medical Journal Articles and Medical or Scientific Reference Publications on Unapproved New Uses of Approved Drugs and Approved or Cleared Medical Devices
April 18, 2008
Download PDF »